Research analysts at Jefferies Group began coverage on shares of Aegerion Pharmaceuticals (NASDAQ: AEGR) in a report released on Tuesday. The firm set a “buy” rating on the stock.

Shares of Aegerion Pharmaceuticals opened at 32.52 on Tuesday. Aegerion Pharmaceuticals has a 52 week low of $11.75 and a 52 week high of $32.63. The stock’s 50-day moving average is currently $28.25. The company’s market cap is $828.5 million.

A number of other firms have also recently commented on AEGR. Analysts at Bank of America initiated coverage on shares of Aegerion Pharmaceuticals in a research note to investors on Tuesday. They set a “buy” rating and a $39.00 price target on the stock. Separately, analysts at Lazard Capital Markets upgraded shares of Aegerion Pharmaceuticals from a “neutral” rating to a “buy” rating in a research note to investors on Monday, February 11th. Finally, analysts at Deutsche Bank raised their price target on shares of Aegerion Pharmaceuticals from $30.00 to $37.00 in a research note to investors on Monday, January 28th. They now have a “buy” rating on the stock.

Aegerion Pharmaceuticals, Inc. (Aegerio) is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat lipid disorders.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.